Specify a stock or a cryptocurrency in the search bar to get a summary
Monte Rosa Therapeutics Inc
GLUEMonte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1"/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts. Address: 321 Harrison Avenue, Boston, MA, United States, 02118
Analytics
WallStreet Target Price
15.83 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures GLUE
Dividend Analytics GLUE
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History GLUE
Stock Valuation GLUE
Financials GLUE
Results | 2019 | Dynamics |